Adults aged ≥65 years are strongly recommended to receive an annual dose of either of 2 enhanced trivalent influenza vaccines (TIVs): 

  • a high-dose influenza vaccine (Fluzone High-Dose)
  • an adjuvanted influenza vaccine (Fluad) 

Influenza-associated mortality rates are highest among adults aged ≥65 years.4 Vaccinating elderly people reduces hospitalisations from influenza and pneumonia, and all-cause mortality.8

The high-dose (Fluzone High-Dose) and adjuvanted (Fluad) TIVs are recommended in preference to quadrivalent influenza vaccines for adults aged ≥65 years. However, neither of these 2 TIVs is preferred over the other. See also Vaccine information.

Page history

Last updated: 
7 June 2018
Last reviewed: 
7 June 2018